静脉免疫树突状细胞疫苗激活抗小鼠黑色素瘤CTL反应机制初探  

A preliminary research on the mechanism of dendritic cell vaccines activate anti-melanoma CTL via intravenous injection

作　　者：齐渊元 王雪[1] 张晗[1] 张立丽[1] 聂红[1] 

机构地区：[1]上海交通大学医学院上海市免疫学研究所,上海200025

出　　处：《现代免疫学》2014年第6期492-496,共5页Current Immunology

基　　金：国家自然科学基金面上项目(30872304);上海市卫生局青年科研项目(2010Y017);上海交通大学医学院基金(12XJ10005)

摘　　要：建立体外诱导分化骨髓来源树突状细胞(dendritic cell,DC)疫苗激活抗小鼠黑色素瘤CTL反应模型。体外分化小鼠骨髓来源树突状细胞并荷载鸡卵清白蛋白OVA257-264,静脉免疫小鼠1周之后接种表达OVA全长蛋白的小鼠黑色素瘤B16,观察成瘤情况并评价免疫效果。结果,体外分化小鼠骨髓来源树突状细胞并荷载OVA257-264肽段,表面表达肽段-主要组织相容性复合物(pMHC)作为第一信号以及共刺激分子CD80以及CD40;体内成瘤实验显示,静脉注射荷载OVA257-264能够抵抗B16-OVA的成瘤。DC疫苗静脉免疫后主要分布于肺部和脾脏。本研究通过静脉注射荷载OVA257-264肽段成熟DC,成功的诱导小鼠CTL免疫反应,抵抗黑色素瘤的成瘤。To establish the bone marrow-derived dendritic cells（DC）vaccine in vitro to activate cytotoxic response in the mouse model of melanoma.Bone marrow-derived DCs were pulsed with OVA257-264 peptide.Mice were inoculated with B16-OVA cells one week after i.v.immunized with DCs.Tumorigenicity and immune effect was evaluated.Bone marrow derived DCs were loaded with OVA257-264 peptides.They expressed a high level of pMHC which serves as the first signal and expressed the costimulatory molecules,CD80 and CD40.In vivo experiments showed that mice were resistant to B16-OVA tumors by intravenous injection of peptide-loaded DCs which were mainly distributed in the lung and spleen.The immune response in melanoma tumorigenicity successfully arose via intravenous injection of OVA257-264-loaded mature DC prepared in vitro.This study successfully induced anti-melanoma CTL reaction by using the intravenous injection of OVA257-264-loaded DC vaccine.

关 键 词：树突状细胞 DC疫苗 黑色素瘤 

分 类 号：R392.12[医药卫生—免疫学]